Warning Letter — ketaminetroches.com
The FDA issued a warning letter to ketaminetroches.com for the unauthorized marketing and distribution of drug products. The Center for Drug Evaluation and Research (CDER) identified regulatory violations following an assessment of the company's online activities.
This action affects online drug distributors, digital marketing teams within the life sciences sector, and regulatory professionals managing pharmaceutical e-commerce compliance.
The issuance of this letter by CDER underscores the FDA's continued focus on the digital distribution of substances that may lack formal FDA approval or required marketing authorizations. This enforcement movement suggests that online platforms operating in the ketamine space are under heightened scrutiny, and firms should evaluate the risk of administrative or legal action if their business models involve selling prescription-grade compounds without verified regulatory pathways.
1. Conduct a comprehensive audit of all website and digital marketing content to ensure every drug claim is supported by a valid marketing authorization. 2. Establish a cross-functional review process involving regulatory and legal teams to approve promotional language before public dissemination. 3. Monitor e-commerce platforms for compliance regarding the distribution and sale of controlled substances.
FDA Warning Letter issued to: ketaminetroches.com. 06/23/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ketaminetrochescom-725148-06232026
Open in openFDA / FDA.gov